A group of experts discuss the current treatment algorithm for NSCLC, as well as novel approaches under investigation, the impact of molecular biomarkers on their treatment decisions, and the importance of clinical trials.
The positive CHMP opinion is based on results from the phase 1b/2 FELIX trial evaluating obe-cel in relapsed/refractory B-cell ALL.
Covers known cancer risk factors, how certain cancers can be prevented, and ongoing research into causes and prevention.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends…
Fruquintinib plus capecitabine demonstrated preliminary efficacy and safety as maintenance therapy in RAS/BRAF wild-type metastatic colorectal cancer.
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
Panelists discuss how amivantamab plus lazertinib therapy for EGFR-mutant non–small cell lung cancer has shown promising survival data while highlighting the importance of managing adverse…
As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running high over a wave of potential practice-changing…
Podcasts | The Hematologist | American Society of Hematology Podcasts The Hematologist offers podcasts that enhance the reading experience by presenting key results and additional insights…
In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with relapsed/refractory multiple myeloma and the…
No recurrences, disease-free survival events, or deaths were reported in select patients with breast cancer who had surgery omitted.
